Knight Therapeutics (TSE:GUD) Hits New 52-Week High – Time to Buy?

Shares of Knight Therapeutics Inc. (TSE:GUD) reached a new 52-week high on Thursday. The stock traded as high as C$11.84 and last traded at C$11.59, with a volume of 3,125 shares trading hands. The stock had previously closed at C$11.26.

Knight Therapeutics Stock Up 4.1%

The stock’s fifty day simple moving average is C$10.53 and its two-hundred day simple moving average is C$8.61. The company has a debt-to-equity ratio of 4.29, a current ratio of 2.28 and a quick ratio of 1.79. The company has a market capitalization of C$1.16 billion, a price-to-earnings ratio of 78.40, a PEG ratio of -1,013.50 and a beta of -0.51.

Knight Therapeutics (TSE:GUD) last posted its quarterly earnings results on Thursday, November 5th. The company reported C($0.03) EPS for the quarter. Knight Therapeutics had a net margin of 2.72% and a return on equity of 1.91%. The business had revenue of C$136.74 million during the quarter. On average, sell-side analysts predict that Knight Therapeutics Inc. will post 0.10 earnings per share for the current fiscal year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc, please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.